Payment overview · 2025
General Payments
$355.44
16 reported records · 13 companies
Healthcare provider profile · identity verified
Veena Reddy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AUSTIN, TX · NPI 1750671137
Verified facts
What the public records show
CMS Open Payments records show Veena Reddy, M.D. received $355.44 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.53 | 13.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.47 | 11.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $36.40 | 10.2% | 2 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $33.98 | 9.6% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.21 | 9.3% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $31.92 | 9.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.69 | 7.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.70 | 7.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.57 | 4.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.27 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.06 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.37 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.27 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.46 | 14 |
| Entertainment | $33.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.47 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $33.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| VANTA ADAPTIVESTIM Normalized: vanta adaptivestim |
Device | Medtronic, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 163 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 24 |
| Sertraline Hcl | Sertraline Hcl | 113 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 105 | 18 |
| Omeprazole | Omeprazole | 93 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 14 |
| Memantine Hcl | Memantine Hcl | 83 | 14 |
| Lisinopril | Lisinopril | 81 | 17 |
| Furosemide | Furosemide | 77 | 16 |
| Gabapentin | Gabapentin | 68 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 66 | 17 |
| Donepezil Hcl | Donepezil Hcl | 64 | 11 |
| Losartan Potassium | Losartan Potassium | 54 | 11 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.44 · 16 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, COMIRNATY, GOMEKLI, INSPIRE, Korlym, NFC-700, OCT OPHTHALMOSCOPE, Ozempic, PANORAMIC OPHTHALMOSCOPE, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, VANTA ADAPTIVESTIM, Wegovy, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error